ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0135

Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression

Joseph Couto1, Elisea Avalos-Reyes2, Amanda McCarthy3, Olga Matlin4, Michele Hamburger5, Gerard Maher6 and Kjel Johnson1, 1CVS Health, Lincoln, RI, 2CVS Health, Irving, TX, 3CVS Health, Greensboro, GA, 4CVS Health, Northbrook, IL, 5Frances Hamburger Institute, Hauppauge, NY, 6Frances Hamburger Institute, Hauppaugue, NY

Meeting: ACR Convergence 2021

Keywords: Cost-Effectiveness, mental health, Psoriatic arthritis, rheumatoid arthritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and SLE. RDs are associated with a high risk for psychiatric comorbidities, particularly depression. The impact of comorbid depression on RD patients could substantially impact clinical and economic outcomes. The purpose of this study is to compare the total cost of care (TCC) and medication adherence in RD patients with and without optimally managed depression (OMD).

Methods: This retrospective cohort study identified RD patients with and without depression and patients with depression only, insured by a large Commercial health plan in the United States between January 1, 2017, and December 31, 2017, who were followed up until December 31, 2019. We defined “sub-optimally-managed depression” (SOMD) as having one or more of the following: suboptimal antidepressant adherence (< 80% portion of days covered (PDC)), at least one inpatient admission or emergency room visit with a primary diagnosis of depression or exceeding $5,000 in claims for place of service (POS) 51-58. We defined “OMD” as patients not meeting any of the previously mentioned criteria. Multiple linear regression was used to model the difference between baseline and follow-up for the different cohorts, adjusting for confounders.

Results: This study included 56,156 patients; the majority were female (68.4%); the mean age was 51.7 years (SD = 17.6). After adjustment, the annualized TCC of patients with OMD+RD was $6,884 (p< 0.001) more than those with RD alone, a difference that was largely driven by medical benefit spend (p< 0.001). Patients with SOMD+RD spent $2,980 (p=0.254) less than those with RD alone. When examining RD-related medical cost differences in patients, those with OMD spent $1,218 (p< 0.001) more than those with RD alone. During the follow-up period, TCC within patients was largely represented by drug costs, as medical benefit costs excluding RD-medication costs represented, on average, 5% of TCC in the RD alone cohort, 5.5% in the RD cohort and 3.5% in the SOMD+RD cohort. There were no significant differences in RD-medication adherence between groups.

Conclusion: In this study, OMD+RD patients spent significantly more in TCC than SOMD+RD patients. Previous research has shown patients with RDs and comorbid depression have poorer clinical outcomes than patients without comorbid depression. Defining suboptimal treatment of disease through administrative claims has inherent limitations, thus further research is required to understand how closely this definition correlates with clinical outcomes. However, given the dominating expense of targeted immunomodulators in treating RD patients, poorer outcomes in patients with comorbid depression do not appear to be readily observed when evaluating patient financial outcomes. It is imperative that as alternative payment models are developed for treating RD patients, provider incentives to manage comorbidities effectively are developed beyond TCC related incentives, as these alone could inadvertently disincentivize effective management of depression and other mental health conditions.

Total Cost Difference Across All Cohorts Adjusted with Multiple Linear Regression

RD Cost Difference Across All Cohorts Adjusted with Multiple Linear Regression

Comparing RD Adherence by Cohort Adjusted with Multiple Linear Regression


Disclosures: J. Couto, CVS Health, 3, 11; E. Avalos-Reyes, CVS Health, 3, 11; A. McCarthy, CVS Health, 3, 11; O. Matlin, CVS Health, 3, 11; M. Hamburger, None; G. Maher, None; K. Johnson, CVS Health, 3, 11.

To cite this abstract in AMA style:

Couto J, Avalos-Reyes E, McCarthy A, Matlin O, Hamburger M, Maher G, Johnson K. Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/comparing-rheumatoid-arthritis-ra-psoriatic-arthritis-pa-and-systemic-lupus-erythematosus-sle-total-cost-of-care-tcc-in-those-with-optimally-managed-depression-to-those-with-sub-optimally-man/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-rheumatoid-arthritis-ra-psoriatic-arthritis-pa-and-systemic-lupus-erythematosus-sle-total-cost-of-care-tcc-in-those-with-optimally-managed-depression-to-those-with-sub-optimally-man/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology